Rosacea therapy update

Advances in Dermatology

Volumn 19, Issue , 2003, Pages 139-170

  Pelle, Michelle T ^a   James, William D ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOIC ACID; AVOBENZONE; AZELAIC ACID; AZITHROMYCIN; BENZOYL PEROXIDE; CLARITHROMYCIN; CLENIA; CLINDAMYCIN; COSMETIC; CYPROTERONE ACETATE; DOXYCYCLINE; DOXYCYCLINE HYCLATE; ERYTHROMYCIN; FINACEA; MACROLIDE; METROLOTION; METRONIDAZOLE; MINOCYCLINE; ORAL CONTRACEPTIVE AGENT; OXYTETRACYCLINE; PLEXION; RETINOIC ACID; ROSANIL; ROSULA; SULFACETAMIDE; SUNSCREEN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TITANIUM DIOXIDE; TSUKUBAENOLIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC OXIDE;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; GASTROINTESTINAL DISEASE; HUMAN; HYPERSENSITIVITY; IMMUNITY; KERATOLYSIS; LASER; LIVER TOXICITY; PHOTOTHERAPY; REVIEW; ROSACEA; SKIN CARE; SKIN SENSITIVITY; TELANGIECTASIA;

HUMANS; ROSACEA;

EID: 0642337435     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (168)

1. Tan JK: A new formulation containing sunscreen (SPF 15) and 1% metronidazole (ROSASOL cream) in the treatment of rosacea. Skin Ther Lett 6:1-2, 2001.
2. Draelos ZD: Silicones in topical dermatologic preparations. Cosmetic Dermatol Jan:35-6, 2000.
3. Draelos ZD: Cosmetics in acne and rosacea. Sem Cutan Med Surg 20:209-214, 2001.
4. Nichols K, Desai N, Lebwohl MG: Effective sunscreen ingredients and cutaneous irritation in patients with rosacea. Cutis 61:344-346, 1998.
5. Lonne-Rahm SB, Fischer T, Berg M: Stinging and rosacea. Acta Dermatol Venereol 79:460-461, 1999.
6. Frosch PJ, Kligman AM: Recognition of chemically vulnerable and delicate skin. In: Frost P, Horwith SN, ed. Principles of Cosmetics for the Dermatologist. St Louis: C Mosby Co, 1987, pp 287-296.
7. Issachar N, Gall Y, Borell T, et al: Ph measurements during lactic acid stinging test in normal and sensitive skin. Contact Dermatitis 36:152-155, 1997.
8. Wilkin JK: Use of topical products for maintaining remission in rosacea. Arch Dermatol 135:79-80, 1999.
9. Weber PJ, Moody BR: Surgical rosacea. Dermatol Surg 28:329-330, 2002.
10. Pye RJ, Burton JL: Treatment of rosacea by metronidazole. Lancet 1:1211-1212, 1976.
11. Nielsen PG: A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol 109:63-65, 1983.
12. Nielsen PG: Treatment of rosacea with 1% metronidazole cream: A double-blind study. Br J Dermatol 108:327-332, 1983.
13. Nielsen PG: The relapse rate for rosacea after treatment with either oral tetracycline or metronidazole cream. Br J Dermatol 109:122, 1983.
14. Dahl M, Jarratt M, Kaplan D, et al: Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol 45:723-730, 2001.
15. Breneman DL, Stewart D, Hevia O, et al: A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis 61:44-47, 1998.
16. Jorizzo JL, Lebwohl M, Tobey RE: The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% twice daily and their vehicles in rosacea: A double-blind clinical trial. J Am Acad Dermatol 39:502-504, 1998.
17. Espagne E, Guillaume JC, Archimbaud A, et al: Double-blind, placebo-vehicle controlled trial of a 0.75% metronidazole gel in the treatment of rosacea. Ann Dermatol Venereol 120:129-133, 1993.
18. Bleicher PA, Charles JH, Sober AJ: Topical metronidazole therapy for rosacea. Arch Dermatol 123:609-614, 1987.
19. Aronson IK, Rumsfield JA, West DP, et al: Evaluation of topical metronidazole gel in acne rosacea. Drug Intell Clin Pharm 21:346-351, 1987.
20. Bjerke JR, Nyfors A, Austad J, et al: Metronidazole 1% cream v placebo cream in the treatment of rosacea. Clin Trials J 26:187-194, 1989.
21. Bitar A, Bourgouin J, Dore N, et al: A double-blind randomized study of metronidazole 1% cream in the treatment of acne rosacea: A placebo controlled study. Drug Invest 2:242-248, 1990.
22. Lowe NJ, Henderson T, Millikan LE, et al: Topical metronidazole for severe and recalcitrant rosacea: A prospective open trial. Cutis 43:283-286, 1989.
23. Del Rosso JQ: A status report on the medical management of rosacea: Focus on topical therapies. Cutis 70:271-275, 2002.
24. Dahl MV, Katz HI, Krueger GG, et al: Topical metronidazole maintains remissions of rosacea. Arch Dermatol 134:679-683, 1998.
25. Barnhorst DA Jr, Foster JA, Chern KC, et al: The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology 103:1880-1883, 1996.
26. Bannatyne RM: Metronidazole, its bioactive metabolites and acne. Curr Med Res Opin 15:298-299, 1999.
27. Akamatsu H, Oguchi M, Nishijima S, et al: The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: A possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res 282:449-454, 1990.
28. Lamp KC, Freeman CD, Klutman NE, et al: Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 36:353-373, 1999.
29. Mallikarjuna Rao C, Ghosh A, Raghothama C, et al: Does metronidazole reduce lipid peroxidation in burn injuries to promote healing? Burns 28:427-429, 2002.
30. Miyachi Y: Potential antioxidant mechanism of action for metronidazole: Implications for rosacea management. Adv Ther 18:237-243, 2001.
31. Miyachi Y, Imamura S, Niwa Y: Antioxidant action of metronidazole: A possible mechanism of action in rosacea. Br J Dermatol 114:231-234, 1986.
32. Grove DI, Mahmoud AAF, Warren KS: Suppression of cell-mediated immunity by metronidazole. Int Arch Allergy Appl Immunol 54:422-427, 1977.
33. Olansky S: Old drug - in a new system - revisited. Cutis 19:852-854, 1977.
34. Blom I, Hornmark AM: Topical treatment with sulfur 10 per cent for rosacea. Acta Dermatol-Venereol 64:358-359, 1984.
35. Sauder DN, Miller R, Gratton D, et al: The treatment of rosacea: The safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatol Treat 8:79-85, 1997.
36. Lebwohl MG, Medansky RS, Russo CL, et al: The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet-R) lotion and metronidazole 0.75% (MetroGel) in the treatment of rosacea. J Geriatr Dermatol 3:183-185, 1995.
37. Arndt KA, Bowers KE: Manual of Dermatologic Therapeutics, ed 6. Philadelphia, Lippincott & Wilkins, 2002, pp 329-343.
38. Fitton A, Goa KL: Azelaic acid: A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 41:780-798, 1991.
39. Akamatsu H, Miyaichi Y, Komura J: Effect of azelaic acid on neutrophils function: A possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res 23:162-166, 1991.
40. Carmichael AJ, Marks R, Graupe KA, et al: Topical azelaic acid in the treatment of rosacea. J Dermatol Treat 4:S19-S22, 1993.
41. Maddin S: A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 40:961-965, 1999.
42. Mills OH, Kligman AM: Topically applied erythromycin in rosacea. Arch Dermatol 112:553-554, 1976.
43. Valsecchi R, Panser B, Reseghetti A: Contact allergy to erythromycin. Contact Dermatitis 34:428, 1996.
44. Van Ketel W: Immediate and delayed-type allergy to erythromycin. Contact Dermatitis 2:363-464, 1976.
45. Lombardi P, Campolmi P, Spallanzani P, et al: Delayed hypersensitivity to erythromycin. Contact Dermatitis 8:416-431, 1982.
46. Martins C, Freitas JD, Goncalo M, et al: Allergic contact dermatitis from erythromycin. Contact Dermatitis 33:360, 1995.
47. Wilkin JK, DeWitt S: Treatment of rosacea: Topical clindamycin versus oral tetracycline. Int J Dermatol 32:65-67, 1993.
48. Ross JI, Snelling AM, Eady EA, et al: Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 144:339-346, 2001.
49. Tan HH, Goh CL, Yeo MG, et al: Antibiotic sensitivity of Propionibacterium acnes isolates from patients with acne vulgaris in a tertiary dermatological referral centre in Singapore. Ann Acad Med Singapore 30:22-25, 2001.
50. Puhvel SM, Sakamoto M: The chemoattractant properties of comedonal contents. J Invest Dermatol 71:324-329, 1978.
51. Jain A, Sangal L, Basal E, et al: Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes-induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J 8:2, 2002.
52. Goldman D: Tacrolimus ointment for the treatment of steroid-induced rosacea: A preliminary report. J Am Acad Dermatol 44:995-998, 2001.
53. Bergman J, Rico MJ: Tacrolimus clinical studies for atopic dermatitis and other conditions. Semin Cutan Med Surg 20:250-259, 2001.
54. Marks R: Concepts in the pathogenesis of rosacea. Br J Dermatol 80:170-177, 1968.
55. Ramelet AA, Perroulaz G: Rosacea: Histopathologic study of 75 cases. Ann Dermatol Venereol 115:801-806, 1988.
56. Marks R: Histogenesis of the inflammatory component of rosacea. Proc R Soc Med 66:742-745, 1973.
57. Marks R, Harcourt-Webster JN: Histopathology of rosacea. Arch Dermatol 100:683-691, 1969.
58. Lachgar S, Charveron M, Aries MF, et al: Inhibitory effects of retinoids on VEGF production by cultured human skin keratinocytes. J Invest Dermatol 109:455, 1997.
59. Gilchrest BA: Treatment of photodamage with topical tretinoin: An overview. J Am Acad Dermatol 36:S27-S36, 1997.
60. Verbenko EV, Katsman LI, Fomina LP: Experience with the retin-A treatment of acne vulgaris and rosacea. Vestn Dermatol Venereol 2:47-50, 1977.
61. Kligman AM: Topical tretinoin for rosacea: A preliminary report. J Dermatol Treat 4:71-73, 1993.
62. Ertl GA, Levine N, Kligman AM: Comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol 130:319-334, 1994.
63. Wilkin JK: Rosacea. Pathophysiology and treatment. Arch Dermatol 130:359-362, 1994.
64. Vienne MP, Ochando N, Borrel MT, et al: Retinaldehyde alleviates rosacea. Dermatology 199:53-56, 1999.
65. Bhawan J, Palko MJ, Lee J, et al: Reversible histologic effects of tretinoin on photodamaged skin. J Geriatr Dermatol 3:62-67, 1995.
66. Saurat JH, Didierjean L, Masgrau E, et al: Topical retinaldehyde on human skin: Biologic effects and tolerance. J Invest Dermatol 103:770-774, 1994.
67. Fluhr JW, Vienne MP, Lauze C, et al: Tolerance profile of retinol, retinaldehyde and retinoic acid under maximized and long term clinical conditions. Dermatology 199:57-60, 1999.
68. Kligman AM, Dogadkina D, Lavker RM: Effects of topical tretinoin on non-sunexposed protected skin of the elderly. J Am Acad Dermatol 29:25-33, 1993.
69. Diaz BV, Lenoir MC, Ladoux A, et al: Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem 275:642-650, 2000.
70. Sharma S, Ghoddoussi M, Gao P, et al: A quantitative angiogenesis model for efficacy testing of chemopreventive agents. Anticancer Res 21:3829-3837, 2001.
71. Bhawan J, Olsen E, Lufrano L, et al: Histologic evaluation of the long-term effects of tretinoin on photodamaged skin. J Dermatol Sci 11:177-182, 1996.
72. Sneddon IB: A clinical trial of tetracycline in rosacea. Br J Dermatol 78:649-652, 1966.
73. Knight AG, Vickers CF: A follow-up of tetracycline-treated rosacea. With special reference to rosacea keratitis. Br J Dermatol 93:577-580, 1975.
74. Maibach H: Second generation tetracyclines, a dermatologic overview: Clinical uses and pharmacology. Cutis 45:411-417, 1991.
75. Thomas J, Walker C, Bradshaw M: Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol 71:1472-1483, 2000.
76. Walker C, Thomas J, Nango S, et al: Long-term treatment with subantimicrobial dose doxycycline exerts no antibacterial effect on the subgingival microflora associated with adult periodontitis. J Periodontol 71:1465-1471, 2000.
77. Golub LM, Sorsa T, Lee HM, et al: Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis. J Clin Periodontol 22:100-109, 1995.
78. Martin RR, Warr GA, Couch RB, et al: Effects of tetracycline on leukotaxis. J Infect Dis 129:110-116, 1974.
79. Forsgren A, Schmeling D, Quie PG. Effect of tetracycline on the phagocytic function of human leukocytes. J Infect Dis 130:412-415, 1974.
80. Marks R, Davies MJ: The distribution in the skin of systemically administered tetracycline. Br J Dermatol 81:448-451, 1969.
81. Taneja OP, Grover NK, Thakur LC, et al: Effects of blood levels of tetracycline and oxytetracycline on hepatic and renal functions in normal subjects. Chemotherapy 20:201-211, 1974.
82. Delaney TJ, Leppard BJ, MacDonald DM: Effects of long term treatment with tetracycline. Acta Dermatol-Venereol 54:487-489, 1974.
83. Bocker R. Estler CJ, Reiner C, et al: Combined toxic effects of tetracycline and ethinyl estradiol on liver function of mice. Res Exp Med 185:151-162, 1985.
84. Sauer GC: Safety of long-term tetracycline therapy for acne. Arch Dermatol 112:1603-1605, 1976.
85. Shapiro LE, Knowles SR, Shear NH: Comparative safety of tetracycline, minocycline and doxycycline. Arch Dermatol 133:1224-1230, 1997.
86. Kvicalova E: Observation of liver functions in protracted treatment of rosacea and perioral dermatitis by tetracycline. Cesk Dermatol 52:378-381, 1977.
87. Robinson MJ, Rywlin AM: Tetracycline-associated fatty liver in the male. Report of an autopsied case. Am J Dig Dis 15:857-862, 1970.
88. Freneaux E, Labbe G, Letteron P, et al: Inhibition of mitochondrial oxidation of fatty acids by tetracycline in mice and man: Possible role in microvesicular steatosis induced by this antibiotic. Hepatology 8:1056-1062, 1988.
89. Deboyser D, Goethas F, Krack G, et al: Investigation into the mechanism of tetracycline-induced steatosis: Study in isolated hepatocytes. Toxicol Appl Pharmacol 97:473-479, 1989.
90. Lloyd-Still JD, Grand RJ, Vawter GF: Tetracycline hepatotoxicity in the differential diagnosis of postoperative jaundice. J Pediatr 84:366-370, 1974.
91. Hunt CM, Washington K: Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 107:1844-1847, 1994.
92. Balestrero S, Ciambellotti A, Parodi A, et al: Minocycline-induced lupus-like syndrome. Int J Dermatol 40:474-475, 2001.
93. Dwyer CM, Cuddihy AM, Kerr RE, et al: Skin pigmentation due to minocycline treatment of facial dermatoses. Br J Dermatol 129:158-162, 1993.
94. Weston WL, Morelli JG: Steroid rosacea in prepubertal children. Arch Pediatr Adolesc Med 154:62-64, 2000.
95. Torresani C: Clarithromycin: A new perspective in rosacea treatment. Int J Dermatol 37:343-349, 1998.
96. Torresani C, Pavesi A, Manara GC: Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol 36:942-946, 1997.
97. th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones.
98. Saihan EM, Burton JL: A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol 102:443-445, 1980.
99. Guilhou JJ, Meynadier J, Guilhou E, et al: Traitement de la Rosacee par le metronidazole. Nouv Presse Med 7:1960-1961, 1978.
100. Stieger M: Metronidazol (Flagyl) als Therapievariante bei "Rosazea" und "Perioraler dermatitis." Z Hautkr 54:671-672, 1978.
101. Rebora A, Drago F, Picciotto A: Helicobacter pylori in patients with rosacea. Am J Gastroenterol 89:1603-1604, 1994.
102. Grilli R: Helicobacter pylori: Related to rosacea? J Am Acad Dermatol 42:536-537, 2000.
103. Mayr-Kanhauser S, Kranke B, Kaddu S, et al: Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. Eur J Gastroenterol Hepatol 13:1379-1383, 2001.
104. Utas S, Ozbakir O, Turasan A, et al: Helicobacter pylori eradication treatment reduces the severity of rosacea. J Am Acad Dermatol 40:433-435, 1999.
105. Coxon A, Pallis LA: Metronidazole neuropathy. J Neurol Neurosurg Psychiatry 39:403, 1976.
106. Caro-Paton T, Carvajal A, Martin de Diego I, et al: Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 44:179-182, 1997.
107. Tanga MR, Analani JA, Kabade SS: Clinical evaluation of metronidazole as an anti-inflammatory agent. Int Surg 60:75-76, 1975.
108. Rustra M, Shubik P: Induction of lung tumors and malignant lymphomas in mice by metronidazole. J Nat Cancer Inst 48:721-729, 1972.
109. Nikolowski J, Plewig G: Oral treatment of rosacea with 13-cis-retinoic acid. Hautarzt 32:575-584, 1981.
110. Schmidt JB, Gebhart W, Raff M, et al: 13-cis-retinoic acid in rosacea. Clinical and laboratory findings. Acta Dermatol-Venereol 64:15-21, 1984.
111. Plewig G, Nikolowski J, Wolff H: Action of isotretinoin in acne, rosacea and Gram-negative folliculitis. J Am Acad Dermatol 6:766-785, 1982.
112. Hoting E, Paul E, Plewig G: Treatment of rosacea with isotretinoin. Int J Dermatol 25:660-663, 1986.
113. Marsden JR, Shuster S, Neugebauer M: Response of rosacea to isotretinoin. Clin Exp Dermatol 9:484-488, 1984.
114. Erdogan FG, Yurtsever P, Aksoy D, et al: Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 134:884-885, 1998.
115. Irvine C, Kumar P, Marks R: Isotretinoin in the treatment of rosacea and rhinophyma. In: Marks R, Plewig G, eds: Acne and Related Disorders: Proceedings of an International Symposium, Cardiff 1988. London, Martin Dunitz, 1989, pp 301-305.
116. Lloyd KM: Surgical correction of rhinophyma. Arch Dermatol 126:721-723, 1990.
117. Jansen T, Plewig G: Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities. Facial Plastic Surg 14:241-253, 1998.
118. Jansen T, Plewig G: The treatment of rosaceous lymphoedema. Clin Exp Dermatol 22:57, 1997.
119. Jungfer B, Jansen T, Przybilla B, et al: Solid persistent facial edema of acne vulgaris: successful treatment with isotretinoin and ketotifen. Dermatology 187:34-37, 1993.
120. Mazzatenta C, Giorgino G, Rubegni P, et al: Solid persistent facial oedema (Morbihan's disease) following rosacea, successfully treated with isotretinoin and ketotifen. Br J Dermatol 137:1020-1021, 1997.
121. Harvey DT, Fenske NA, Glass LF: Rosaceous lymphedema: A rare variant of a common disorder. Cutis 61:321-324, 1998.
122. Smith KW: Perioral dermatitis with histopathologic features of granulomatous rosacea: successful treatment with isotretinoin. Cutis 46:413-415, 1990.
123. Krause MH, Torricelli R, Kundig T, et al. Dapsone in granulomatous rosacea. Hautarzt 48:246-248, 1997.
124. Bormann G, Gaber G, Fischer M, et al: Dapsone in rosacea fulminans. J Eur Acad Dermatol Venereol 15:465-467, 2001.
125. Spirov G, Berova N, Vassilev D: Effect of oral inhibitors of ovulation in treatment of rosacea and dermatitis perioralis in women. Austral J Dermatol 12:145-154, 1971.
126. Mauss J: Cyproterone therapy of papulopustular rosacea in women. Hautarzt 32:94-95, 1981.
127. Aizawa H, Niimura M: Oral spironolactone therapy in male patients with rosacea. J Dermatol 19:293-297, 1992.
128. Akamatsu H, Zouboulis CC, Orfanos CE: Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5 alpha-dihydrotestosterone in vitro. J Invest Dermatol 100:660-662, 1993.
129. Rebora A: The management of rosacea. Am J Clin Dermatol 3:489-496, 2002.
130. Wilkin JK: Effect of subdepressor clonidine on flushing reactions in rosacea. Arch Dermatol 119:211-214, 1983.
131. Bernstein JE, Soltani K: Alcohol-induced rosacea flushing blocked by naloxone. Br J Dermatol 107:59-61, 1982.
132. Wollina U: The response of erythematous rosacea to ondansetron. Br J Dermatol 140:538-568, 1999.
133. Wilkin JK: Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol 20:202-205, 1989.
134. Forstinger C, Kittler H, Binder M: Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol 41:775-777, 1999.
135. Dicken CH: Treatment of the red nose with argon laser. Mayo Clin Proc 61:893-895, 1986.
136. Noe JM, Finley J, Rosen S, et al: Postrhinoplasty "red nose": Differential diagnosis and treatment by laser. Plast Reconstr Surg 67:661-664, 1981.
137. Arndt KA: Argon laser therapy of small cutaneous vascular lesions. Arch Dermatol 118:220-224, 1982.
138. Barsky SH, Rosen S, Geer D, et al: Port wine stains, evolution and therapy: A computer assisted analysis. J Invest Dermatol 74:154, 1980.
139. Sadick NS: A structural approach to nonablative rejuvenation. Cosmet Dermatol 15:39-43, 2002.
140. Lowe NJ, Behr KL, Fitzpatrick R, et al: Flash lamp pumped dye laser for rosacea-associated telangiectasia and erythema. J Dermatol Surg Oncol 17;522-525, 1991.
141. West TB, Alster TS: Comparison of the long-pulse dye (590-595 nm) and KTP (532 nm) lasers in the treatment of facial and leg telangiectasias. Dermatol Surg 24:221-226, 1998.
142. Vasily DB: Use of 532 nm diode-pumped frequency-doubled laser and contact cooling device to enhance clearing of facial telangiectasia. Cosmet Dermatol 15:19-22, 2002.
143. Scheepers JH, Quaba AA: Clinical experience in the treatment of the "red nose" using the flashlamp-pumped pulsed dye laser (585 nm). Aesthetic Plast Surg 18:57-60, 1994.
144. Anderson RR, Parrish JA: Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 220:524-527, 1983.
145. Dixon JA, Heuther S, Rotering R: Hypertrophic scarring in argon laser treatment of port wine stains. Plast Reconstr Surg 73:771-777, 1984.
146. Herne KB, Zachary CB: New concepts in non-ablative rejuvenation. Cosmet Dermatol 13:23-27, 2000.
147. Zelickson BD, Kilmer SL, Bernstein E, et al: Pulsed dye laser therapy for sun damaged skin. Lasers Surg Med 25:229-236, 1999.
148. Silver BE, Livshots YL: Preliminary experience with the KTP/532 nm laser in the treatment of facial telangiectasia. Cosmet Dermatol 9:61-64, 1996.
149. Weiss RA, Weiss MA, Beasley KL, et al: Rejuvenation of photoaged skin: 5 years results with intense pulsed light of the face, neck, and chest. Dermatol Surg 28:1115-1119, 2002.
150. Goldman MP. Weiss RA: Treatment of poikiloderma of Civatte on the neck with an intense pulsed light source. Plastic Reconstr Surg 107:1376-1381, 2001.
151. Bjerring P, Clement M, Heickendorff L, et al: Selective nonablative wrinkle reduction by laser. J Cutan Laser Ther 2:9-15, 2000.
152. Moreno Arias GA, Ferrando J: Intense pulsed light for melanocytic lesions. Dermatol Surg 27:397-400, 2001.
153. Cliff S. Misch K: Treatment of mature port wine stains with the PhotoDerm VL. J Cutan Laser Ther 1:101-104, 1999.
154. Beasley KL, Weiss RA, Weiss MA: New parameters for intense pulsed light rejuvenation with a thermoelectrically chilled crystal delivery system. Cosmetic Dermatol 15:14-16, 2002.
155. Goldberg DJ, Cutler KB: Nonablative treatment of rhytids with intense pulsed light. Lasers Surg Med 26:196-200, 2000.
156. Bitter PH: Noninvasive rejuvenation of photodamaged skin using serial, full-face intense pulsed light treatments. Dermatol Surg 26:835-843, 2000.
157. Kirn TF: Intense pulsed light eradicates Demodex mites. Skin All News Jun:37, 2002.
158. Wilder D: VascuLight experience with over 1,000 patients: Two year study of cutaneous vascular lesion treatment with an intense pulsed light and laser source. Clinical Application Notes 1999; ESC Medical Systems Ltd. Vol 8 (2).
159. Weiss RA, Goldman MP, Weiss MA: Treatment of poikiloderma of Civatte with an intense pulsed light source. Dermatol Surg 26:823-828, 2000.
160. Angermeier MC: Treatment of facial vascular lesions with intense pulsed light. J Cutan Laser Ther 1:95-100, 1999.
161. Raulin C, Hellwig S, Schonermark MP: Treatment of a nonresponding port-wine stain with a new pulsed light source (PhotoDerm VL). Lasers Surg Med 21:203-208, 1997.
162. Raulin C, Weiss RA, Schonermark MP: Treatment of essential telangiectasias with an intense pulsed light source (Photoderm VL). Dermatol Surg 23:941-946, 1997.
163. Raulin C, Schroeter CA, Weiss RA, et al: Treatment of port-wine stains with a noncoherent pulsed light source. A retrospective study. Arch Dermatol 135:679-683, 1999.
164. Taub AF: Treatment of rosacea with intense pulsed light. J Drugs Dermatol 3:254-259, 2003.
165. Levy JL:. Intense pulsed light treatment for chronic facial erythema of systemic lupus erythematosus: a case report. J Cutan Laser Ther 2:195-198, 2000.
166. Ruiz-Esparza J, Goldman MP, Fitzpatrick RE, et al: Flashlamp-pumped pulsed dye laser treatment of telangiectasia. J Dermatol Surg Oncol 19:1000-1003, 1993.
167. Nyirady J, Bergfeld W, Ellis C, et al. Tretinoin cream 0.02% for the treatment of photodamaged facial skin: A review of 2 double-blind clinical studies. Cutis 68:135-142, 2001.
168. Nyirady J: Evaluation of the cumulative irritation potential of tretinoin: Review of 2 clinical studies. Cosmetic Dermatol 15:33-36, 2002.